New Releases from NCBI BookshelfNivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: Opdivo (nivolumab), in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma: Reimbursement Recommendation [Internet].Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: Opdivo (nivolumab), in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma: Reimbursement Recommendation [Internet].
What Is the Reimbursement Recommendation for Opdivo Plus Yervoy?
